Earlier, Novavax received a substantial financial boost due to its strategic partnership with French pharmaceutical and healthcare firm Sanofi (NASDAQ:SNY). The partnership – inked on May 10 – centers on a Covid vaccine program called Nuvaxovid and involved a $500 million upfront milestone payment, alleviating "concerns about the company's financial stability." However, the belief among JPMorgan analysts now is that, prior to today's implosion, NVAX stock prices "substantially overvalue" the sales that Nuva ...

Investment Overview Novavax Seals Sensational Sanofi Deal In Q1 2024 Prior to Q1 earnings Novavax had warned investors that "conditions or events existed that raised substantial doubt about our ability to continue as a going concern" - the reasons for this can be traced to its failure to establish its COVID vaccine, Nuvaxovid, alongside Moderna's (MRNA) Spikevax and Pfizer's (PFE) Comirnaty as a preferred vaccine option for major governments' - here is what I wrote in May: Novavax is arguably best known for ...

Zacks Investment Research Image Source: This surge in share price can be attributed to Novavax's recently signed multi-billion dollar deal with pharma giant Sanofi (SNY) to market its protein-based COVID-19 vaccine and also use it to develop novel COVID-19- influenza combination vaccines. The positive cashflows generated from this deal were a major reason that the company removed its 'going concern' warning. Solid Partner in Sanofi The collaboration deal with Sanofi likely breathes new life for Novavax, whi ...

Core Viewpoint - Novavax is experiencing increased attention in the market, with significant factors influencing its stock performance, including earnings estimates and revenue growth [2][11]. Earnings Estimate Revisions - Analysts' revisions of earnings estimates are crucial, as increases in these estimates typically lead to higher stock fair values, prompting investor buying [3]. - The consensus earnings estimate for Novavax is $0.49 for the current fiscal year, reflecting a year-over-year increase of +109.1% [4]. - The Zacks Rank for Novavax is 2 (Buy), indicating potential outperformance in the near term based on earnings estimate revisions [5][11]. Revenue Growth - Revenue growth is essential for sustaining earnings growth; Novavax's revenue for the last reported quarter was $93.86 million, showing a year-over-year increase of +16% [18]. - The consensus sales estimate for the current quarter is $429.83 million, indicating a year-over-year change of +1.3% [17]. - For the next fiscal year, the sales estimate is projected to decline by -44.7% to $553.03 million [17]. Valuation - Novavax is graded D in terms of valuation, suggesting it is trading at a premium compared to its peers [10]. - Valuation multiples such as P/E, P/S, and P/CF are critical for assessing whether the stock is overvalued or undervalued [9][19]. Performance Metrics - Over the past month, Novavax shares have returned +7.6%, outperforming the Zacks S&P 500 composite's +3.8% [12]. - The company has surpassed consensus EPS estimates two times over the last four quarters [19].

The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 84, positioning it in the top 34% of all 250+ industries. The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Remember to apply Zacks.com to follow these and more stock-moving metr ...

Nvidia (NASDAQ:NVDA) has become the face of artificial intelligence and its stock has responded in kind. Shares are up 200% over the past year and over 800% since the release of ChatGPT, which sparked an AI tsunami. Yet there is a world of stocks that are outperforming Nvidia. While the technology sector provides opportunity with companies like Super Micro Computer (NASDAQ:SMCI) far outstripping the chipmaker's gains, investors should widen their lens even further. Vital Farms (VITL) Source: Poravute Siriph ...

What a difference a few months make. Vaccine specialist Novavax (NVAX -1.32%) started the year poorly, continuing with the issues it has encountered since mid-2021. However, several developments have jolted Novavax's stock since January. The company's shares are up by just under 200% this year. Can it keep up that momentum through the next 12 months? Let's find out. Novavax faced significant uncertainty entering the year, but a recent partnership with Sanofi (SNY 0.92%), a much larger biotech, helped dispel ...

The the stock of vaccine maker has fallen by 15.87% in the past month, lagging the Medical sector's gain of 1.74% and the S&P 500's gain of 3.53%. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-a ...

Does it make sense to invest in COVID-19 vaccine stocks in 2024? It should make sense, at least in theory, since U.S. health regulators effectively gave Novavax (NASDAQ:NVAX) the green light to target a specific Covid-19 variant. Yet, it's too late to buy Novavax stock with confidence as meme-stock madness sent the share price to the moon already. I'll bet you never imagined that there would be a connection between GameStop (NYSE:GME) and Novavax. Yet, in these bizarre times, there's actually a link between ...

Core Viewpoint - Novavax has filed a regulatory application with the EMA to update its protein-based COVID-19 vaccine for the 2024/2025 vaccination campaign, aligning with EMA and WHO guidance to target the JN.1 variant [1][2][4]. Company Developments - Novavax's stock has increased by 192.1% year-to-date, contrasting with a 4.1% decline in the industry [3]. - Sanofi will gain global co-marketing rights for Novavax's COVID-19 vaccine starting next year, with Novavax eligible to receive up to $1.2 billion, including $500 million upfront and milestone payments, along with tiered double-digit percentage royalties on sales [6][13]. - The partnership with Sanofi alleviates previous concerns about Novavax's ability to continue as a 'going concern' [7]. Vaccine Efficacy and Market Position - The updated vaccine targets the JN.1 variant but is also effective against currently circulating strains, including KP.2 and KP.3 [8]. - Novavax's COVID-19 vaccine is currently authorized in the EU for individuals aged 12 and older, with a similar filing submitted to the FDA [10]. - Compared to Pfizer and Moderna, Novavax faced challenges during the last vaccination season due to delayed vaccine approval and launch, but early participation in the upcoming season may present new opportunities [12]. Future Plans and Innovations - Novavax is working with global regulatory authorities to secure approvals for the updated vaccine [9]. - The company plans to expand its pipeline using funds from the Sanofi deal, including developing a new approach for H5N1 bird flu vaccination and advancing technology for mucosal vaccination and high-density nanoparticles [14].